Ranbaxy Laboratories Ltd (RANB.BO)

RANB.BO on Bombay Stock Exchange

703.65INR
30 Jan 2015
Change (% chg)

Rs-4.35 (-0.61%)
Prev Close
Rs708.00
Open
Rs708.00
Day's High
Rs714.00
Day's Low
Rs695.75
Volume
87,503
Avg. Vol
120,489
52-wk High
Rs724.95
52-wk Low
Rs308.00

RANB.BO

Chart for RANB.BO

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: 0.53
Market Cap(Mil.): Rs299,071.19
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.BO Industry Sector
P/E (TTM): -- 37.76 38.54
EPS (TTM): -19.13 -- --
ROI: -- 18.79 18.06
ROE: -- 19.44 18.83
Search Stocks

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

31 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

31 Jan 2015

UPDATE 1-Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON, Jan 30 - India's Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the U.S. Federal Trade Commission said on Friday.

31 Jan 2015

Sun Pharmaceutical wins U.S. approval to buy Ranbaxy

WASHINGTON, Jan 30 - Sun Pharmaceutical Industries Ltd has won U.S. approval to buy Ranbaxy Laboratories Ltd on condition that it sells its interest in a generic anti-bacterial medicine, the Federal Trade Commission said on Friday.

31 Jan 2015

Ranbaxy Dec-quarter net loss widens on forex loss

MUMBAI - Indian generic drugmaker Ranbaxy Laboratories Ltd reported a wider loss in the December quarter, hurt by foreign exchange losses and higher finance costs.

28 Jan 2015

India's Ranbaxy Dec qtr net loss widens on forex loss

MUMBAI, Jan 28 - Indian generic drugmaker Ranbaxy Laboratories Ltd reported a wider loss in the December quarter, hurt by foreign exchange losses and higher finance costs.

28 Jan 2015

Nifty falls to one-month low, tracking weak China

MUMBAI - The Nifty fell for a third consecutive day on Tuesday, closing at a one-month low, as investors cashed out positions tracking a selloff in Chinese markets, hurting blue-chips such as Oil and Natural Gas Corp.

09 Dec 2014

CORRECTED-Indian shares fall to one-month low, tracking weak China

(Corrects to say shares fell for a third consecutive day, not second, in paragraph 1)

09 Dec 2014

Sun Pharma, Ranbaxy gain after regulator approves deal

Reuters Market Eye - Sun Pharmaceutical Industries gains 1.4 percent, Ranbaxy Laboratories up 2.8 percent

09 Dec 2014

CCI clears Sun Pharma-Ranbaxy deal

MUMBAI - The Competition Commission of India (CCI) approved generic drugmaker Sun Pharmaceutical Industries' $3.2 billion bid to buy Ranbaxy Laboratories, but ordered the firms to divest seven products to ensure the deal doesn't harm competition.

09 Dec 2014

Earnings vs. Estimates

Search Stocks